EGFR 20 外显子插入（EGFR ex20ins）突变是非小细胞肺癌（NSCLC）中除 EGFR 19 外显子缺失（19-Del）和 21 外显子 L858R 点突变（21-L858R）两大常见突变外的 EGFR 第三大突变，占所有 NSCLC ...

点击蓝字关注我们【导读】脑转移是表皮生长因子受体（epidermal growth factor receptor， ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...

肺癌脑转移是肺癌患者治疗失败和死亡的重要原因，对于携带表皮生长因子受体（EGFR）突变的肺腺癌（LUAD）患者而言，脑转移更是导致靶向治疗失效的关键因素。在亚洲非吸烟的 LUAD 患者中，EGFR 突变比例高达 66.3%，且近 29% 的患者在初诊时就已发现脑转移。经过 3 年酪氨酸激酶抑制剂（TKI）治疗，脑转移的患病率从初诊时的 25% 飙升至 45% 。尽管脑转移危害巨大，但目前对于 ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor ...

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Ovarian cancer (OC), the most lethal gynecological malignancy, is the fifth leading cause of cancer-related death in women.

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March ...